New drug cocktail aims to outsmart resistant lung cancer

NCT ID NCT03778229

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug combination or a placebo. The main goal is to see how many people's tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: osimertinib and savolitinib (two oral drugs)
What this could lead to: If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard therapy.
What could go wrong: This is a phase 2 trial, so it is still early. The combination may not work better than current options, and side effects from two drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

367 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients must be ≥18 years of age (≥20 years of age in Japan). All genders are permitted. * Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy. * Documented radiologic disease progression on 1L osimertinib. * MET amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment. * Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional sample for central testing which fulfils the following requirements: Obtained following progression on previous osimertinib therapy; obtained within 2 years of submission for MET analysis; sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual. * At least 1 lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI which is suitable for accurate repeated measurements. If only 1 measurable lesion exists, it is acceptable to be used as long as baseline tumour assessment scans are done at least 14 days after the screening tumour sample collection is performed. * Prior lines of therapy in locally advanced/metastatic setting: Only prior 1L osimertinib treatment in metastatic setting is permitted. * Adequate haematological function defined as: * Absolute neutrophil count ≥1500/μL * Haemoglobin ≥9 g/dL (no transfusion in the past 2 weeks) * Platelets ≥100,000/μL (no transfusion in the past 10 days) * Adequate liver function * ALT, AST ≤2.5 x ULN with TBL ≤ ULN OR * TBL \>ULN to ≤1.5x ULN with ALT and AST ≤ ULN * Adequate renal function - defined as a serum creatinine \<1.5 times the institutional ULN OR a glomerular filtration rate ≥50 mL/min. Confirmation of creatinine clearance is only required when creatinine is only required when creatinine is \>1.5 times ULN. * Adequate coagulation parameters: INR \<1.5 and activated partial thromboplastin time \<1.5 x ULN unless patients are receiving therapeutic anti coagulation which affects these parameters. * Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin for ≥2 weeks. The use of direct oral anticoagulants such as apixaban/rivaroxaban will be accepted as treatment for cancer related thromboembolism treatment. The use of warfarin for oral anticoagulation is not recommended. * ECOG/WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks. * Females must be using highly effective contraceptive measures, should not be breast feeding and must have a negative pregnancy test if of childbearing potential, or must have evidence of non-childbearing potential. * Males with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 6 months following discontinuation of study drug. Exclusion Criteria: * Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy. * As judged by the investigator, active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhoea Grade ≥2, malabsorption syndrome or previous significant bowel resection). * Any of the following cardiac diseases currently or within the last 6 months: Unstable angina pectoris Congestive heart failure (New York Heart Association \[NYHA\] ≥Grade 2) Acute myocardial infarction Stroke or transient ischemic attack Uncontrolled hypertension (blood pressure \[BP\] ≥150/95 mmHg despite medical therapy). Mean resting correct QT interval (QTcF) \>470 msec for women and \>450 msec for men at Screening, obtained from 3 ECGs using the screening clinic ECG machine derived QTcF value. Any factors that may increase the risk of QTcF prolongation or risk of arrhythmic events such as heart failure, chronic hypokalaemia not correctable with supplements, congenital or familial long QT syndrome, family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECGs, eg, complete left bundle branch block, third degree heart block, second degree heart block, P-R interval \>250 msec. Acute coronary syndrome * Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy. * Major surgical procedures ≤28 days of beginning study drug or minor surgical procedures ≤7 days * Evidence of severe or uncontrolled systemic diseases, including renal transplant, active bleeding diatheses or uncontrolled hypertension, which in the investigator's opinion makes it undesirable for the patient to participate * Active hepatitis B or C or known serious active infection e.g. tuberculosis or human immunodeficiency virus. Viral testing is not required for assessment of eligibility for the study. * Known serious active infection including, but not limited to, tuberculosis, or human immunodeficiency virus (positive human immunodeficiency virus 1/2 antibodies). * Presence of other active cancers, or history of treatment for invasive cancer, within the last 5 years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, non-invasive) are eligible, as are patients with history of non-melanoma skin cancer. * Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment. * Past medical history of interstitial lung disease(ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD. * History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs, * Prior or current treatment with a 3rd generation EGFR-TKI other than osimertinib * Prior or current treatment with savolitinib or another MET inhibitor (eg, foretinib, crizotinib, cabozantinib, onartuzumab, capmatinib). * Any cytotoxic chemotherapy, investigational agents or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days prior to the first dose of study treatment with the exception of monotherapy osimertinib which may continue uninterrupted during screening. * Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4, strong inhibitors of CYP1A2 within 3 weeks of the first dose of study treatment (including St John's Wort). * Participation in another clinical study with a cytotoxic, investigational product (IP), or other anticancer drug for the treatment of advanced NSCLC if received IP from that study within 14 days of the first dose of study treatment. * Known hypersensitivity to the active or inactive excipients of osimertinib or savolitinib or drugs with a similar chemical structure or class.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Los Angeles, California, 90024, United States
Research Site

Sacramento, California, 95817, United States
Research Site

Washington D.C., District of Columbia, 20016, United States
Research Site

Baltimore, Maryland, 21201, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

Brooklyn, New York, 11220, United States
Research Site

Philadelphia, Pennsylvania, 19111, United States
Research Site

Pittsburgh, Pennsylvania, 15232, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Barretos, 14784-400, Brazil
Research Site

Curitiba, 80810-050, Brazil
Research Site

Goiânia, 74093-300, Brazil
Research Site

Porto Alegre, 90540-140, Brazil
Research Site

Porto Alegre, 90610-000, Brazil
Research Site

Rio de Janeiro, 22271-110, Brazil
Research Site

Salvador, 41950-640, Brazil
Research Site

São José do Rio Preto, 15090-000, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

São Paulo, 01509-900, Brazil
Research Site

Calgary, Alberta, T2N 5G2, Canada
Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Newmarket, Ontario, L3Y 2P9, Canada
Research Site

North York, Ontario, M2K 1E1, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Santiago, 7500713, Chile
Research Site

Santiago, 7520349, Chile
Research Site

Santiago, 8420383, Chile
Research Site

Aalborg, 9100, Denmark
Research Site

Herlev, 2730, Denmark
Research Site

København Ø, 2100, Denmark
Research Site

Næstved, 4700, Denmark
Research Site

Odense, 5000, Denmark
Research Site

Vejle, 7100, Denmark
Research Site

Dijon, 21079, France
Research Site

Marseille, 13915, France
Research Site

Nantes, 44093, France
Research Site

Paris, 75020, France
Research Site

Paris, 75248, France
Research Site

Rennes, 35033, France
Research Site

Bangalore, 560064, India
Research Site

Chennai, 600035, India
Research Site

Kolkata, 700160, India
Research Site

New Delhi, 110085, India
Research Site

Avellino, 83100, Italy
Research Site

Florence, 50134, Italy
Research Site

Milan, 20133, Italy
Research Site

Milan, 20141, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Padova, 35128, Italy
Research Site

Parma, 43126, Italy
Research Site

Perugia, 06132, Italy
Research Site

Peschiera del Garda, 37019, Italy
Research Site

Fukuoka, 812-8582, Japan
Research Site

Hiroshima, 730-8518, Japan
Research Site

Kanazawa, 920-8641, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8566, Japan
Research Site

Sapporo, 003-0804, Japan
Research Site

Sayama, 589-8511, Japan
Research Site

Sunto-gun, 411-8777, Japan
Research Site

Wakayama, 641-8510, Japan
Research Site

Yokohama, 241-0815, Japan
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suwon, 16247, South Korea
Research Site

Córdoba, 14004, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Málaga, 29010, Spain
Research Site

Valencia, 46026, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Hsinchu, 300, Taiwan
Research Site

Kaohsiung City, 83301, Taiwan
Research Site

New Taipei City, 23561, Taiwan
Research Site

Taichung, 402, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Hà Nội, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.